Researchers at Yale Pursuing COVID-19 Vaccine Based on Powerful Yale Platform
Yale pathologist John “Jack” Rose believes a proven vaccine platform he pioneered decades ago using a livestock virus called vesicular stomatitis virus (VSV) could produce better immunity than other vaccine candidates, and be scaled up quickly to meet global demand.
Yale Launches Clinical Trial for Drug to Treat Severe COVID-19 Patients
Yale researchers will begin a clinical trial at Yale-New Haven Hospital to test the effectiveness of a drug called ibudilast (MN-166) for treating acute respiratory distress syndrome (ARDS), a life-threatening lung condition developed by some of the most seriously ill COVID-19 patients.
New cancer drug shrinks tumors, reduces side effects, in animal studies
A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates greater potency against a wider variety of cancers, as well as against solid tumors, and also produces fewer side effects compared to others in the class.
Invicro Collaborates with Yale’s Dr. David Rimm to Expand the Utility of Quanticell™ for Clinical Pathology Applications
BOSTON--(BUSINESS WIRE)--Invicro LLC, a Konica Minolta Company announced it has entered into a strategic research partnership with industry leading pathologist, Dr. David Rimm, MD, PhD, at The Yale University School of Medicine to advance the development of Quanticell, Konica Minolta’s proprietary tissue biomarker detection technology.
Geneticist Sidi Chen Receives Large Award Which Will Further His Breast Cancer Work
This Department of Defense award goes to the “best and brightest in their fields,” and recognizes “creative and innovative individuals.” Investigators are chosen for their ability “to go beyond conventional thinking” in their respective areas of expertise.
Humanized Mice Lead to Breakthroughs in Blood Cancers
Humanized mice created at Yale are opening new avenues of research into cancers caused by disorders in the production of blood, such as acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Until recently, such research was hindered because human blood stem cells are difficult to grow in cell cultures or to engraft in mice.
The Race to the Next Target
To Parker Sulkowski, the next step was obvious, but he also knew that others would be racing to get there first. A PhD student in the lab of Peter Glazer, MD, PhD, Dr. Sulkowski was about to take what he learned from their groundbreaking study of glioma and look for other targets.
Trainee-Led Study Seeks to Better Understand All-Cause Mortality in Schizophrenia Patients
A new study led by a Yale Department of Psychiatry trainee sought to better understand why people with schizophrenia have dramatically increased all-cause mortality, and whether living with severe mental illness accelerates the aging process.
Yale Scientists Breach Brain Barriers to Attack Tumors
The brain is a sort of fortress, equipped with barriers designed to keep out dangerous pathogens. But protection comes at a cost: These barriers interfere with the immune system when faced with dire threats such glioblastoma, a deadly brain tumor for which there are few effective treatments.